Biohaven (BHVN) Ltd. announced that it has commenced an underwritten public offering of $150M of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. Biohaven intends to use the net proceeds received from the offering for general corporate purposes. J.P. Morgan and Goldman Sachs & Co. are acting as the book-running managers of the offering.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Strategic Pipeline Focus and Cost Management Drive Buy Rating for Biohaven Ltd.
- Biohaven reports Q3 EPS ($1.64), consensus ($1.61)
- Biohaven price target lowered to $30 from $75 at Piper Sandler
- Biohaven price target lowered to $16 from $33 at BTIG
- Hold Rating on Biohaven Ltd. Amid Liquidity Challenges and Uncertain Clinical Outcomes